Cancer Family
Lipomatous Neoplasm
CI-CAN-00000216Explore in graph →
Non-malignant55 active trials1 approved drugs9 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000216Explore in graph →
Clinical trials
155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06498648 | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02923778 | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 2 | Sep 25, 2026 |
| clinicaltrials |
| NCT07686367 | Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | not yet recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 0 | Sep 25, 2026 | clinicaltrials |
| NCT06422806 | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | recruiting | Phase 3 | 365 | National Cancer Institute (NCI)NIH | 3 | Sep 22, 2026 | clinicaltrials |
| NCT05694871 | Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 77 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06025747 | A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas | recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06843967 | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823491 | Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall | not yet recruiting | Phase 3 | 228 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07802652 | Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma(IMMUSARC-7012) | not yet recruiting | Phase 2 | 80 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03307616 | Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04438824 | Palbociclib and INCMGA00012 in People With Advanced Liposarcoma | active not recruiting | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma(STRASS2) | recruiting | Phase 3 | 250 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Sep 10, 2026 | clinicaltrials |
| NCT05711615 | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 104 | Milton S. Hershey Medical CenterOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07797270 | Ultrasound-Guided Emulsification Therapy in the Clinical Treatment of Subcutaneous Lipomas | not yet recruiting | N/A | 30 | Chinese PLA General HospitalOTHER | 0 | Sep 1, 2026 | clinicaltrials |
| NCT06389799 | A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)(PERELI) | recruiting | Phase 2 | 33 | Lund University HospitalOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07261657 | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | recruiting | Early Phase 1 | 8 | Seth PollackOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04044768 | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | active not recruiting | Phase 2 | 52 | USWM CT, LLCINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | recruiting | Phase 1 / Phase 2 | 107 | STORM Therapeutics LTDINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT06903208 | RFA for Superficial Lipomas | recruiting | N/A | 10 | Columbia UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04715191 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | recruiting | Phase 1 | 24 | Baylor College of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741877 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma('SARATOGA') | not yet recruiting | Phase 2 | 80 | Iovance Biotherapeutics, Inc.INDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07734805 | Radiological Diagnosis of Pediatric Neck Swellings | active not recruiting | — | 50 | Sohag UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06083883 | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | recruiting | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07237425 | Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma | recruiting | Phase 1 | 56 | Glonova Pharma Co., LtdINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07377747 | Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma(ReLaPSe) | recruiting | — | 100 | Australia and New Zealand Sarcoma AssociationOTHER | 8 | Jul 15, 2026 | clinicaltrials |
| NCT06414434 | BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | active not recruiting | Phase 1 | 24 | Michael Wagner, MDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04668300 | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma(DOSa) | active not recruiting | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT02846987 | Study of Abemaciclib in Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT06957431 | Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | recruiting | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT06820164 | Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride | recruiting | Phase 1 / Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03361436 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | active not recruiting | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05886634 | A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
Data updated 12 hours agoSource updated Sep 29, 2026source: clinicaltrials